The clinical application of ctDNA to predict response to neoadjuvant chemoradiotherapy in patients with locally-advanced rectal cancer

被引:2
|
作者
Pezeshki, Parmida Sadat [1 ,2 ]
Ghalehtaki, Reza [2 ,3 ]
机构
[1] Univ Tehran Med Sci, Sch Med, Tehran, Iran
[2] Univ Tehran Med Sci, Canc Res Inst, Radiat Oncol Res Ctr, Qarib St,Keshavarz Blvd, Tehran, Iran
[3] Univ Tehran Med Sci, Canc Inst, Dept Radiat Oncol, IKHC, Tehran, Iran
关键词
CIRCULATING TUMOR DNA;
D O I
10.1186/s40364-023-00521-5
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Colorectal cancer is a major cause of cancer-related deaths worldwide. A third of colorectal cancers reside in the rectum. Many patients with rectal cancer present in the locally-advanced stage which needs multi-modality therapy usually starting with neoadjuvant chemo-radiotherapy followed by surgery and adjuvant systemic chemotherapy. Total neoadjuvant therapy, defined as the preoperative administration of both neoadjuvant chemoradiotherapy and systemic chemotherapy is also an evolving treatment that can be delivered if indications for preoperative chemotherapy exist. Identifying biomarkers to predict response to neoadjuvant therapy, can improve patient selection for a non-surgical, active surveillance approach. Circulating tumor DNA (ctDNA) can be detected in about 75% of patients with locally-advanced rectal cancer (LARC) at the baseline and in about 15-20% of patients in the post-neoadjuvant, or postoperative setting. ctDNA clearance rate after delivering neoadjuvant chemoradiotherapy, or integrating baseline ctDNA with other conventional markers of clinical response can be a promising marker to select and monitor patients on the "watch and wait" approach. In this article, we aimed to integrate the recent findings and provide a unique insight into the utilization of preoperative ctDNA to predict clinical response in patients with LARC. We also sought to highlight the potential areas for future research in this field. Further studies with a larger number of participants from diverse populations and settings are needed to increase external validity of such investigations and determine the role of ctDNA in guiding clinical decisions and management of patients with LARC.
引用
收藏
页数:4
相关论文
共 50 条
  • [1] The clinical application of ctDNA to predict response to neoadjuvant chemoradiotherapy in patients with locally-advanced rectal cancer
    Parmida Sadat Pezeshki
    Reza Ghalehtaki
    Biomarker Research, 11
  • [2] Novel biomarkers that predict response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer
    Hasan, Adria
    Demidova, Elena V.
    Czyzewicz, Philip
    Devarajan, Karthik
    Einarson, Margret B.
    Baldwin, Donald
    Golemis, Erica A.
    Meyer, Joshua E.
    Arora, Sanjeevani
    CANCER RESEARCH, 2024, 84 (06)
  • [3] The predictive role of ctDNA for response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer (NEORECT trial)
    Gruenewald, T.
    Dintner, S.
    Hoeck, M.
    Sommer, F.
    Kroencke, T.
    Messmann, H.
    Anthuber, M.
    Stueben, G.
    Trepel, M.
    Maerkl, B.
    Claus, R.
    ONCOLOGY RESEARCH AND TREATMENT, 2019, 42 : 54 - 54
  • [4] The predictive role of ctDNA for response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer (NEORECT trial)
    Hoeck, M.
    Gruenewald, T.
    Sommer, F.
    Kroencke, T.
    Messmann, H.
    Anthuber, M.
    Stueben, G.
    Trepel, M.
    Maerkl, B.
    Dintner, S.
    Claus, R.
    STRAHLENTHERAPIE UND ONKOLOGIE, 2019, 195 : S201 - S202
  • [5] The predictive role of ctDNA for response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer (NEORECT trial)
    Hoeck, M.
    Gruenewald, T.
    Dintner, S.
    Sommer, F.
    Kroencke, T.
    Messmann, H.
    Anthuber, M.
    Stueben, G.
    Trepel, M.
    Bruno, M.
    Claus, R.
    STRAHLENTHERAPIE UND ONKOLOGIE, 2020, 196 (SUPPL 1) : S150 - S150
  • [6] Analysis of Clinical characteristics to predict pathologic complete response for patients with locally advanced rectal cancer treated with neoadjuvant chemoradiotherapy
    Peng, Haihua
    Wang, Chengtao
    Xiao, Weiwei
    Lin, Xiaodan
    You, Kaiyun
    Dong, Jun
    Wang, Zhenyu
    Yu, Xiaobi
    Zeng, Zhifan
    Zhou, Tongchong
    Gao, Yuanhong
    Wen, Bixiu
    JOURNAL OF CANCER, 2018, 9 (15): : 2687 - 2692
  • [7] CEA levels predict tumor response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer
    Lili Shen
    Chao Li
    Jingwen Wang
    Jin Fan
    Ji Zhu
    Oncology and Translational Medicine, 2022, 8 (04) : 180 - 185
  • [8] Predicting the patterns of response to neoadjuvant chemoradiotherapy in patients with locally advanced rectal cancer
    Martinez, C. Graham
    Rombouts, A.
    Bosch, S.
    van de Water, C.
    Vierrijp, K.
    de Wilt, H.
    Simmer, F.
    Nagtegaal, I.
    VIRCHOWS ARCHIV, 2020, 477 : S184 - S185
  • [9] Neoadjuvant chemoradiotherapy and chemotherapy in patients with locally advanced rectal cancer
    Soliman, A.
    Attia, N.
    Khalaf, M.
    Attia, A.
    Fakhry, H.
    ANNALS OF ONCOLOGY, 2016, 27 : 93 - 93
  • [10] Systemic inflammatory indices predict tumor response to neoadjuvant chemoradiotherapy for locally advanced rectal cancer
    Lai, Sicong
    Huang, Liang
    Luo, Shuangling
    Liu, Zhanzhen
    Dong, Jianghui
    Wang, Liping
    Kang, Liang
    ONCOLOGY LETTERS, 2020, 20 (03) : 2763 - 2770